PA 21

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 584977

CAS#: 125200-63-7

Description: PA 21 is an iron-based noncalcium phosphate binder that prevents vascular calcification in chronic renal failure rats.


Price and Availability

Size
Price

Size
Price

Size
Price

PA 21 is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 584977
Name: PA 21
CAS#: 125200-63-7
Chemical Formula: C9H15O6P2-
Exact Mass: 250.0617
Molecular Weight: 250.1879
Elemental Analysis: C, 43.21; H, 6.04; O, 38.37; P, 12.38


Synonym: PA 21; PA21

IUPAC/Chemical Name: 6-Acryloyloxyhexyl phosphate

InChi Key: UNLGHUTUQNFLSO-UHFFFAOYSA-L

InChi Code: InChI=1S/C9H17O6P/c1-2-9(10)14-7-5-3-4-6-8-15-16(11,12)13/h2H,1,3-8H2,(H2,11,12,13)/p-2

SMILES Code: O=P([O-])([O-])OCCCCCCOC(C=C)=O


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>3 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
2934.99.90.01


References

1: Yaguchi A, Tatemichi S, Takeda H, Kobayashi M. PA21, a novel phosphate binder, improves renal osteodystrophy in rats with chronic renal failure. PLoS One. 2017 Jul 13;12(7):e0180430. doi: 10.1371/journal.pone.0180430. eCollection 2017. PubMed PMID: 28704404; PubMed Central PMCID: PMC5509238.

2: Yaguchi A, Yonekubo S, Maruyama I, Tatemichi S, Maruyama K, Kobayashi M. Comparison of Phosphate Binding Capacities of PA21, A Novel Phosphate Binder, with those of other Phosphate Binders in vitro and in vivo. Drug Res (Stuttg). 2016 May;66(5):262-9. doi: 10.1055/s-0035-1569328. Epub 2016 Jan 13. PubMed PMID: 26761712.

3: Koiwa F, Terao A. Dose-response efficacy and safety of PA21 in Japanese hemodialysis patients with hyperphosphatemia: a randomized, placebo-controlled, double-blind, Phase II study. Clin Exp Nephrol. 2017 Jun;21(3):513-522. doi: 10.1007/s10157-016-1299-z. Epub 2016 Jul 7. Erratum in: Clin Exp Nephrol. 2017 Jun;21(3):523. PubMed PMID: 27389681; PubMed Central PMCID: PMC5486467.

4: Xie D, Ye N, Li M. A systematic review on the efficacy and safety of PA21 versus sevelamer in dialysis patients. Int Urol Nephrol. 2018 May;50(5):905-909. doi: 10.1007/s11255-017-1774-9. Epub 2018 Jan 2. Review. PubMed PMID: 29294216.

5: Wilhelm M, Gaillard S, Rakov V, Funk F. The iron-based phosphate binder PA21 has potent phosphate binding capacity and minimal iron release across a physiological pH range in vitro. Clin Nephrol. 2014 Apr;81(4):251-8. PubMed PMID: 24656315.

6: Wüthrich RP, Chonchol M, Covic A, Gaillard S, Chong E, Tumlin JA. Randomized clinical trial of the iron-based phosphate binder PA21 in hemodialysis patients. Clin J Am Soc Nephrol. 2013 Feb;8(2):280-9. doi: 10.2215/CJN.08230811. Epub 2012 Nov 2. PubMed PMID: 23124782; PubMed Central PMCID: PMC3562865.

7: Phan O, Maillard M, Peregaux C, Mordasini D, Stehle JC, Funk F, Burnier M. PA21, a new iron-based noncalcium phosphate binder, prevents vascular calcification in chronic renal failure rats. J Pharmacol Exp Ther. 2013 Aug;346(2):281-9. doi: 10.1124/jpet.113.204792. Epub 2013 May 22. PubMed PMID: 23697346.

8: Koiwa F, Yokoyama K, Fukagawa M, Akizawa T. Long-Term Assessment of the Safety and Efficacy of PA21 (Sucroferric Oxyhydroxide) in Japanese Hemodialysis Patients With Hyperphosphatemia: An Open-Label, Multicenter, Phase III Study. J Ren Nutr. 2017 Sep;27(5):346-354. doi: 10.1053/j.jrn.2017.02.007. Epub 2017 May 24. PubMed PMID: 28550969.

9: Floege J, Covic AC, Ketteler M, Rastogi A, Chong EM, Gaillard S, Lisk LJ, Sprague SM; PA21 Study Group. A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients. Kidney Int. 2014 Sep;86(3):638-47. doi: 10.1038/ki.2014.58. Epub 2014 Mar 19. PubMed PMID: 24646861; PubMed Central PMCID: PMC4150998.

10: Koiwa F, Yokoyama K, Fukagawa M, Terao A, Akizawa T. Efficacy and safety of sucroferric oxyhydroxide compared with sevelamer hydrochloride in Japanese haemodialysis patients with hyperphosphataemia: A randomized, open-label, multicentre, 12-week phase III study. Nephrology (Carlton). 2017 Apr;22(4):293-300. doi: 10.1111/nep.12891. PubMed PMID: 27496336; PubMed Central PMCID: PMC5347921.

11: Geisser P, Philipp E. PA21: a novel phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease. Clin Nephrol. 2010 Jul;74(1):4-11. PubMed PMID: 20557860.

12: Tang Q, Xiong S, Liang X, Kuai X, Wang Y, Wang C, Feng Z, Zhu J. Human monoclonal anti-protective antigen antibody for the low-dose post-exposure prophylaxis and treatment of Anthrax. BMC Infect Dis. 2018 Dec 10;18(1):640. doi: 10.1186/s12879-018-3542-6. PubMed PMID: 30526504; PubMed Central PMCID: PMC6288905.

13: Geach T. Clinical trials. Less of the same--PA21 can reduce pill burden in patients with hyperphosphataemia. Nat Rev Nephrol. 2014 Jun;10(6):297. doi: 10.1038/nrneph.2014.62. Epub 2014 Apr 8. PubMed PMID: 24709845.

14: Gutzwiller FS, Pfeil AM, Ademi Z, Blank PR, Braunhofer PG, Szucs TD, Schwenkglenks M. Cost Effectiveness of Sucroferric Oxyhydroxide Compared with Sevelamer Carbonate in the Treatment of Hyperphosphataemia in Patients Receiving Dialysis, from the Perspective of the National Health Service in Scotland. Pharmacoeconomics. 2015 Dec;33(12):1311-24. doi: 10.1007/s40273-015-0320-9. PubMed PMID: 26334991; PubMed Central PMCID: PMC4661221.

15: Koiwa F, Terao A. Erratum to: Dose-response efficacy and safety of PA21 in Japanese hemodialysis patients with hyperphosphatemia: a randomized, placebo-controlled, double-blind, Phase II study. Clin Exp Nephrol. 2017 Jun;21(3):523. doi: 10.1007/s10157-016-1350-0. PubMed PMID: 27832343.

16: Maidin MS, Song AA, Jalilsood T, Sieo CC, Yusoff K, Rahim RA. Construction of a novel inducible expression vector for Lactococcus lactis M4 and Lactobacillus plantarum Pa21. Plasmid. 2014 Jul;74:32-8. doi: 10.1016/j.plasmid.2014.05.003. Epub 2014 May 28. PubMed PMID: 24879963.

17: Khanna B, Spelbring JE, Innis BL, Robertson BH. Characterization of a genetic variant of human hepatitis A virus. J Med Virol. 1992 Feb;36(2):118-24. PubMed PMID: 1316423.

18: Floege J, Covic AC, Ketteler M, Mann JF, Rastogi A, Spinowitz B, Chong EM, Gaillard S, Lisk LJ, Sprague SM; Sucroferric Oxyhydroxide Study Group. Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients. Nephrol Dial Transplant. 2015 Jun;30(6):1037-46. doi: 10.1093/ndt/gfv006. Epub 2015 Feb 16. PubMed PMID: 25691681; PubMed Central PMCID: PMC4438742.

19: Cada DJ, Ingram KT, Levien TL, Baker DE. Canagliflozin. Hosp Pharm. 2013 Nov;48(10):855-67. doi: 10.1310/hpj4810-855. PubMed PMID: 24421439; PubMed Central PMCID: PMC3859282.

20: Phan O, Maillard M, Malluche HH, Stehle JC, Funk F, Burnier M. Effects of Sucroferric Oxyhydroxide Compared to Lanthanum Carbonate and Sevelamer Carbonate on Phosphate Homeostasis and Vascular Calcifications in a Rat Model of Chronic Kidney Failure. Biomed Res Int. 2015;2015:515606. doi: 10.1155/2015/515606. Epub 2015 Jun 29. PubMed PMID: 26221597; PubMed Central PMCID: PMC4499607.